2930627-60-2

Camostat-d6 is intended for use as an internal standard for the quantification of camostat (Item No. 16018) by GC- or LC-MS. Camostat (50 µM) inhibits entry of vesicular stomatitis virus (VSV) particles pseudotyped with severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike glycoprotein in Calu-3 cells and primary human lung epithelial cells.1 It reduces the number of SARS-CoV-2 genomic equivalents, a marker of infection, in Calu-3 cells. Camostat inhibits sodium channel function in human airway epithelial cells (IC50 = 50 nM) and enhances mucociliary clearance in sheep.2 Dietary administration of camostat (1 mg/kg) inhibits the production of TNF-α and chemokine (C-C motif) ligand 2 (CCL2) by monocytes, as well as proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis.3WARNING This product is not for human or veterinary use.

[1] MARKUS HOFFMANN. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.[J]. Cell, 2020: 271-280.e8. DOI: 10.1016/j.cell.2020.02.052
[2] JUAN PABLO MAIANTI. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones[J]. Nature, 2014, 511 7507: 94-98. DOI: 10.1038/nature13297
[3] JUNYA GIBO. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity[J]. Laboratory Investigation, 2004, 85 1: 75-89. DOI: 10.1038/labinvest.3700203